This educational activity presented at JADPRO 2026 will provide US-based oncology advanced practice providers and oncologists with practical, case-based education on the evolving role of antibody-drug conjugates (ADCs) in non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). Expert faculty will review approved and emerging ADC therapies; biomarker-informed patient selection and testing considerations; proactive monitoring and management of common and serious treatment-related adverse events, including interstitial lung disease/pneumonitis; and APP-led multidisciplinary strategies to support patient education, adherence, care coordination, and quality of life. Interactive polling and real-time question-and-answer discussion will support application of evidence-based, guideline-concordant approaches in clinical practice.
Credit & MOC Details
Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.
Credit types
MOC types
FDA REMS
Qualifies for MIPS
Target Specialties
Pricing
99% of listed courses are free
156 of 157 courses listed here are free.
Collected from the provider’s public pages
Specialties served/covered
- Allergy & Clinical Immunology
- Anatomic & Clinical Pathology
- Cardiovascular Disease
- Communication & Shared Decision-Making
- Critical Care Medicine
- Dermatology
- Diagnostic Radiology
- Endocrinology, Diabetes & Metabolism
- Family Medicine
- Gastroenterology
- Gastrointestinal Surgery
- General Internal Medicine
- General Pediatrics
- General Surgery
- Gynecologic Oncology
- Hematology
- Infectious Disease
- Interventional Cardiology
- Maternal-Fetal Medicine
- Medical Oncology
- Nephrology
- Neurocritical Care
- Neurology
- Neuromuscular Medicine
- Obstetrics & Gynecology
- Ophthalmology
- Pediatric Gastroenterology
- Pediatric Infectious Diseases
- Pulmonary Disease
- Rheumatology
- Sleep Medicine
- Surgical Oncology
- Transplant Hepatology
- Urological Oncology
- Urology
- Vascular Neurology
- Cardio-Vascular
- Cross-Specialty
- Emergency & Critical Care
- GI & Liver
- Infectious Disease
- Internal Medicine
- Medical Subspecialties
- Neurology
- Ob/Gyn
- Oncology & Hematology
- Pathology & Lab
- Pediatrics
- Primary care
- Radiology
- Surgery
- Urology
- No reviews yet. Be the first to share yours.
Pricing
Free
Reported to ACCME by the provider
- Live
- Credit · Up to 1 credit
- Commercial Support
-
WhenOct 15, 2026
-
Answers in CME Inc. (AiCME) Navigating ADC Therapy in Lung Cancer: An APP Guide to Selection, Safety, and Care Coordination
-
Answers in CME Inc. (AiCME) New Frontiers in Small Cell Lung Cancer: Getting Ready for the Emergence of B7-H3 Directed ADCs
-
Answers in CME Inc. (AiCME) Rapid Roundup 2025 in NSCLC: Keeping Up with ADC Therapies Driving Precision Lung Cancer Care
-
Global Learning Collaborative Spotlight on B7-H3 ES-SCLC: Applying ADC Evidence in Real-World Practice
-
PRIME Education, Inc. (PRIME®) The Latest Clinical Evidence for Antibody-Drug Conjugates in ES-SCLC
-
Clinical Care Options, LLC (dba Decera Clinical Education) HER2- and TROP2-Directed ADCs in NSCLC: Patient Selection, Treatment Sequencing, and Toxicity Management in a Rapidly Evolving Landscape
